EUVIMEDEUVIMED entdecken
Open Access

Relationship of Fibroblast Growth Factor 23 With Hospitalization for Heart Failure and Cardiovascular Outcomes in Patients Undergoing Cardiac Surgery

Felix Hofer iD, Andreas Hammer iD, Ulrike Pailer iD, Lorenz Koller iD, Niema Kazem iD, Eva Steinacher iD, Barbara Steinlechner iD, Martin Andreas, Günther Laufer, Johann Wojta iD, Thomas A Zelniker iD, Christian Hengstenberg iD und 2 weitere

Journal of the American Heart Association · 2023

DOI: 10.1161/jaha.122.027875 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of the American Heart Association, 2023. Verfasst von Felix Hofer und 13 weiteren Autor:innen. Beteiligte Einrichtung: Division of Cardiology, Department of Internal Medicine II Medical University of Vienna Vienna Austria. Hauptthemen laut MEDLINE: Atrial Fibrillation, Heart Failure. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background Fibroblast growth factor 23 (FGF‐23) is crucial in regulating phosphate and vitamin D metabolism and is moreover associated with an increased cardiovascular risk. The specific objective of this study was to investigate the influence of FGF‐23 on cardiovascular outcomes, including hospitalization for heart failure (HHF), postoperative atrial fibrillation, and cardiovascular death, in an unselected patient population after cardiac surgery. Methods and Results Patients undergoing elective coronary artery bypass graft and/or cardiac valve surgery were prospectively enrolled. FGF‐23 blood plasma concentrations were assessed before surgery. A composite of cardiovascular death/HHF was chosen as primary end point. A total of 451 patients (median age 70 years; 28.8% female) were included in the present analysis and followed over a median of 3.9 years. Individuals with higher FGF‐23 quartiles showed elevated incidence rates of the composite of cardiovascular death/HHF (quartile 1, 7.1%; quartile 2, 8.6%; quartile 3, 15.1%; and quartile 4, 34.3%). After multivariable adjustment, FGF‐23 modeled as a continuous variable (adjusted hazard ratio for a 1‐unit increase in standardized log‐transformed biomarker, 1.82 [95% CI, 1.34–2.46]) as well as using predefined risk groups and quartiles remained independently associated with the risk of cardiovascular death/HHF and the secondary outcomes, including postoperative atrial fibrillation. Reclassification analysis indicated that the addition of FGF‐23 to N‐terminal pro‐B‐type natriuretic peptide provides a significant improvement in risk discrimination (net reclassification improvement at the event rate, 0.58 [95% CI, 0.34–0.81]; P

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Atrial FibrillationHeart FailureHumansFemaleAgedMaleFibroblast Growth Factor-23BiomarkersCoronary Artery BypassHospitalizationFibroblast Growth Factors

Stichwörter der Autor:innen

cardiac surgerycardiovascular deathfibroblast growth factor 23hospitalization for heart failurepostoperative atrial fibrillation

Substanzen

Fibroblast Growth Factor-23BiomarkersFibroblast Growth Factors

Autor:innen und Institutionen

  • Division of Cardiology, Department of Internal Medicine II Medical University of Vienna Vienna Austria.
  • Vienna Health Care Group Vienna Austria.
  • Department of Anesthesiology Medical University of Vienna Vienna Austria.
  • Department of Cardiac Surgery Medical University of Vienna Vienna Austria.

ORCID-Profile: Felix Hofer, Andreas Hammer, Ulrike Pailer, Lorenz Koller, Niema Kazem, Eva Steinacher, Barbara Steinlechner, Johann Wojta, Thomas A Zelniker, Christian Hengstenberg, Alexander Niessner, Patrick Sulzgruber

Zitieren

APA

Hofer, F., Hammer, A., Pailer, U., Koller, L., Kazem, N., Steinacher, E., Steinlechner, B., Andreas, M., Laufer, G., Wojta, J., Zelniker, T. A., Hengstenberg, C., Niessner, A., & Sulzgruber, P. (2023). Relationship of Fibroblast Growth Factor 23 With Hospitalization for Heart Failure and Cardiovascular Outcomes in Patients Undergoing Cardiac Surgery. Journal of the American Heart Association. https://doi.org/10.1161/jaha.122.027875

Vancouver

Hofer F, Hammer A, Pailer U, Koller L, Kazem N, Steinacher E, et al. Relationship of Fibroblast Growth Factor 23 With Hospitalization for Heart Failure and Cardiovascular Outcomes in Patients Undergoing Cardiac Surgery. Journal of the American Heart Association. 2023. doi:10.1161/jaha.122.027875

BibTeX
@article{Hofer2023,
  author = {Hofer, Felix and Hammer, Andreas and Pailer, Ulrike and Koller, Lorenz and Kazem, Niema and Steinacher, Eva and Steinlechner, Barbara and Andreas, Martin and Laufer, Günther and Wojta, Johann and Zelniker, Thomas A and Hengstenberg, Christian and Niessner, Alexander and Sulzgruber, Patrick},
  title = {Relationship of Fibroblast Growth Factor 23 With Hospitalization for Heart Failure and Cardiovascular Outcomes in Patients Undergoing Cardiac Surgery},
  journal = {Journal of the American Heart Association},
  year = {2023},
  doi = {10.1161/jaha.122.027875}
}
Kostenlos starten →